Trial Profile
A Multi-center Randomized Phase II Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2023
Price :
$35
*
At a glance
- Drugs Plerixafor (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 06 Jul 2023 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.
- 06 Jul 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2024.
- 11 Aug 2022 Status changed from recruiting to active, no longer recruiting.